Reading between the lines in the 2Q26 Management Discussion and Analysis of Techno Medical Public Company Limited (TM): Revenue up 2.5%. Net profit up 33.3%. And a 2Q26 price increase in a quarter when sales fell 1.1%.
The numbers
Disposables carry a modest top-line gain
Techno Medical imports and distributes medical devices to Thai hospitals and, through a subsidiary, runs a Bangkok nursing home, The Parents. The 2Q26 MD&A reports on the six months to June. In 6M26, revenue from sales rose 2.5% YoY to Bt339m. Disposable equipment and supplies, 99% of sales, grew 2.8%. Medical equipment and instrument sales fell 26.1% on lower sales of coronary artery fixation devices.
Margins widen on China-sourced products
Gross margin on product sales rose to 40.5% in 6M26 from 37.4% in 6M25. The MD&A attributes the improvement to a larger share of lower-cost products imported from China and a price increase in 2Q26. Distribution costs rose 7.3%, and administrative expenses rose 11.1%, the latter on consultant fees and new hires. Net profit rose 33.3% YoY to Bt14m, a net margin of 4.2%.
Nursing-care losses narrow as patient numbers rise
Service income at The Parents rose 34.6% YoY to Bt14m, with average patients up to around 45–50 from 40–45. The service gross loss narrowed to 15.0% of service income from 25.0%. The MD&A notes relatively high fixed costs, such as depreciation and wages.
What the numbers don’t show
Comparing the 2Q26 MD&A with 1Q26, a couple of things stand out.
A 2Q26 price increase and lower 2Q26 sales
The 1Q26 MD&A explained disposables growth through a shift toward lower-cost products imported from China. It made no reference to pricing. The 2Q26 MD&A adds a second driver: a policy to raise product prices in 2Q26 because of rising shipping costs. The filing says this increased sales and improved gross margins.
The tables in the 2Q26 MD&A cover only the six-month period. On a standalone basis, sales rose 6.0% YoY in 1Q26, then fell 1.1% YoY to Bt163m in 2Q26, the quarter in which prices were raised.
Government hospital receivables: from "can collect" to "continuous rise"
Both MD&As trace the company’s overdue receivables to sales to government hospitals. In 1Q26, the MD&A described a problem with late payment from these customers, adding that the company can collect in the future. The 2Q26 MD&A does not repeat that statement. It says government hospitals are likely to pay more slowly in 2026, resulting in a continuous rise in outstanding receivables.
The 2Q26 filing also discloses a Bt0.4m bad-debt write-off. Impairment and bad-debt charges were Bt0.3m in 1Q26 and Bt1.7m for 6M26. In 6M25, there was a net reversal of Bt0.1m when the company collected receivables more than 12 months overdue.